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As part ofthe recent meeting "Current Perspectives inAcid Inhibitory Therapy" held
atYale University School ofMedicine, a large group ofexperts met to discuss and debate
a number ofunsolved issues withregard to Helicobacterpylori infection in man. The dis-
cussion leaders were G.N.J. Tytgat and I.N. Marks, and the panelists were J. Calam, D.
Cave, J. Freston, R.H. Hunt, G. Krejs, F. Megraud and M. Quina.
J. Calam addressed the issue ofthe effect ofH. pylori eradication on acid secretion in
general, and in duodenal ulcer in particular. He stated that there were consistent falls in
acid secretion in duodenal ulcer patients with regard to basal secretion and the response
to GRP stimulation; the response to pentagastrin stimulation after H. pylori cure was vari-
able. Functional dyspepsia patients, on the other hand, showed no fall in basal secretion,
and he drew attention to a recently completed 24-hour pH study by Andre Blum's group
in which gastric acidity increased significantly following H. pylori eradication. J. Calam
speculated as to the cause ofthe seemingly different responses in duodenal ulcer and func-
tional dyspepsia patients. According to McColl, stepped infusions of gastrin show a
greater sensitivity of the parietal cell mass to gastrin in patients with duodenal ulcer dis-
ease than in functional dyspepsia. For some unexplained reason, H. pylori infection is
affecting the gastric corpus in functional dyspepsia in a way that negates the effect ofele-
vated gastrin, while this does not happen in duodenal ulcer patients. It would, therefore,
be extremely important, to also look at the state ofthe mucosa both in antrum and corpus
to see whether mucosal alterations correlate with the changes in acid secretory capacity
changes after eradication.
J. Freston stated that there was probably no relationship of H. pylori to gastroe-
sophageal reflux disease. The organism does not inhabit esophageal epithelium and, when
present in Barrett's epithelium, does not appear to be associated with an inflammatory
response. He suggested thatH. pylori may extend in the proximal stomach with time, par-
ticularly with ppIc therapy, and may eventually interfere with LES function. There are
also anecdotal reports of symptomatic remissions in patients with mild GERD after H.
pylori eradication, and he speculated that this may be linked to resolution in gastrin lev-
els following H. pylorn eradication. He did not think gastrin per se has an effect on the
LES, but that the effect of gastrin on acid secretion may be relevant. Alternatively, some
patients develop GERD symptoms after successful cure of the infection. Attention was
drawn to the not infrequent finding of a fall in pH (from around 1.4 or 1.5 to 1.3) follow-
ing H. pylori eradication. Whether this increased acidity is contributing in people who do
not necessarily have frank esophagitis but have an acid sensitive esophagus requires fur-
ther study. In addition, some patients do gain weight after H. pylori cure, which may also
favor GERD manifestation. Finally it was noted that there are some patients with GERD
in whom H. pylori eradication appears to be associated with increased acidity and a con-
sequent increased requirement for PPIs.
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R.H. Hunt was asked whether progression ofglandular atrophy during prolonged PPI
therapy is H. pylori related. He cited the Klinkenberg-Knol and subsequent Kuipers' stud-
ies in support of progression of atrophic gastritis on long-term PPI therapy, but was
unclear as to whether this progression was related to possible variations in H. pylori strain
and virulence. Progression of atrophic gastritis on prolonged PPI therapy is not seen in
patients not-infected with H. pylori. J. Freston stressed that progression and proximal
spread of glandular atrophy on PPI therapy may occur in the absence ofH. pylori infec-
tion but could notexclude thepossibility thatH. pylorimay be apotentiating factor. While
not against H. pylori eradication in such patients, he did not believe that the progression
ofatrophy on PPI therapy was necessarily linked to H. pylori infection. G. Tytgat did not
share the latter view. D. Cave cited a recent Blaser study showing that sonicates of viru-
lent H. pylori reactants with cagA and vac A positivity induced atrophy ofmouse mucosa
within 48 hours of a single injection. G. Tytgat added that H. pylori virulence (CagA pos-
itivity) was linked also to therapiddevelopmentofatrophy in man. J. Freston, when asked
to give an opinion on the reversibility ofglandular atrophy and intestinal metaplasia after
H. pylorieradication, stated simply that glandular atrophy does notappear to be reversible.
D. Cave regarded the question of whether gastric metaplasia in the bulb regresses
after successful H. pylori eradication as a contentious one. Although Dr. Northfield's
group had recently found that gastric metaplasia regresses over a period of time, he felt
that there are problems with regard to measurements, representative biopsies and appro-
priate staining. He stated, furthermore, that duodenal ulcers may occur with or without
gastric metaplasia in the duodenum, and that the ltatter is not an obligatory component of
the disease. R. Hunt stated that two recent studies had shown a good correlation between
acid secretory status and gastric metaplasia in the bulb and thought that if so, regression
would take a long time, possibly years. G. Tytgat thought it possible that a primary duo-
denal ulcer may destroy the entire metaplastic focus, which might again become manifest
once healing had occurred. He noted that a "kissing" type ulcer may show less metapla-
sia than a single one. M. Quina commented on the role ofH. pylori eradication in bleed-
ing H. pylori-associated ulcers. H. pylorieradication, while important, was not sufficient
in the setting, and should always be followed by maintenance treatment with an acid
inhibitory agent. The role ofH. pylori eradication in NSAID induced bleeding ulcers had
not been resolved, but he noted that some workers advise H. pylori eradication in all
patients before the start of NSAID therapy. B.I. Hirschowitz considered H. pylori and
NSAIDS to be two independent risk factors for bleeding, and that H. pylori eradication
would eliminate at least one ofthem. R.H. Huntquestioned the routine use ofmaintenance
therapy following successful H. pylori eradication other than in elderly poor-risk patients
and in young patients living away from medical facilities. J. Freston stated that misopros-
tol has an advantage over H2receptorantagonists in terms ofulcerprophylaxis in patients
on NSAIDS, particularly with regard to gastric ulcer prophylaxis.
G. Krejs discussed the possible role ofH. pylori in the heterogeneous group of func-
tional or, non-ulcer, dyspepsia (NUD). Functional dyspepsia was defined as discomfort in
the upper abdomen - continuous or intermittent - unassociated with evidence of struc-
tural change such as ulcer or malignancy and, by convention, included H. pylori gastritis.
He noted that many studies show a 10 to 12 percent preponderance ofH. pylori positivity
in functional dyspepsiacompared to control groups, andthatH.pyloripositivepatients with
functional dyspepsia have marginally more severe symptoms than those withH. pylorineg-
ative functional dyspepsia. Although studies using earlier and less efficacious eradication
regimens have failed to show a cleardifference, he felt that there must be an H. pyloripos-
itive functional dyspepsia subgroup ofpatients who would benefit from H. pylori eradica-
tion. The problem, however, was in identifying the latter subgroups. Consideration should
be given to studying the different clinical subsets of functional dyspepsia i.e. ulcer-like,
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reflux-like, dysmotility-like and non-specific subsets. Stratification of patients in the ulcer-
like subset according to age, acid secretory response to GRP and H. pylori virulence may
also be warranted.
F. Megraud discussed the role of PPIs in overcoming metronidazole resistance in
PPI triple but especially PPI quadruple regimens. Data on this topic were limited because
H. pylori strains are almost always categorized as susceptible or resistant without refer-
ence to the exact minimal inhibitory concentration (MIC). The current cut-off of 8 mg/l is
probably not correct, and data relating to the exact MIC to clinical efficacy were required.
We need to know up to what level of resistance a given regimen is able to eradicate, and
whether a few resistant mutant colonies were clinically relevant if the vast majority were
sensitive. He was uncertain as to whether PPIs per se overcame metronidazole resistance.
F. Megraud also stated that different animals harbor different species ofHelicobacter,
and that more than 10 species have been described. He added that while H. pylori is the
main species adapted to man, man may occasionally be infected by other species. The first
to be described was Gastrospirillum hominis, recently renamed H. heilmanii, an organism
that is not currently cultivable in vitro and that can be detected only on morphology in his-
tological preparations. The organism produces urease and may, thus, mimic H. pylori by
tests based on urease production. H. heilmanii may produce inflammatory changes, but it
is not known whether it induces ulcers. F. Megraud was not aware of any case in which
H. felis was cultured from the stomach. He noted that there were two sources ofH.felis:
the stomach ofpets, especially cats and dogs, and the otherthe stomach ofpigs. They have
been studied using a PCR technique, and the organisms in cats and dogs are a subspecies.
Possible differences in H. pylori in the antrum and body ofthe stomach in man were con-
sidered, but F. Megraud did not think that available data substantiated this. He stated that
about 10 to 15 percent ofpeople in developed countries may harbor two or more different
strains of H. pylori. Mention was also made of other organisms that may cause inflam-
mation in the stomach such as the Anisakis larvae in Japan which may also produce gas-
tric metaplasia and lead to carcinoma in situ, Giardia or Candida which may colonize a
pre-existing ulcer, and HSV-I. The suggestion was made that herpes (HSV-I) should per-
haps be considered in patients with non-H. pylori non-NSAID-associated ulcers.
Both G. Tytgat and F. Megraud felt that other PPIs were as effective as omeprazole
in enhancing antibiotic efficacy. It was noted that lansoprazole has a higher MIC than
omeprazole againstH. pylori, and F. Megraud suggested that reported differences may be
linked to differences in the percentage of strains resistant to antibiotics. I.N. Marks drew
attention to the initial perception that omeprazole was more effective than other PPIs in
enhancing antibiotic efficacy. The early lansoprazole/amoxycillin data was appreciably
lower than the 80 to 90 percent eradication rates claimed with omeprazole/amoxycillin
combinations at the time. Against the latter background, the lansoprazole/amoxycillin,
and for that matter, the pantoprazole/amoxycillin data ofless than 45 percent seemed dis-
mal. This led to the perception that the omeprazole/amoxycillin combination was the
treatment of choice. It was only later than one appreciated that the omeprazole/amoxy-
cillin eradication rates varied from 30 to 80 percent, and that the rates in most of the
Western world and elsewhere, other than select centers in Germany, were in the region of
40 to 60 percent. R.H. Hunt concurred and indicated that his meta-analysis of omepra-
zole/amoxycillin data averages 61 percent. He stated that omeprazole/clarithromycin dual
therapy was more predictable, with an average eradication rate of 71 percent. He cited
data suggesting that omeprazole increases the concentration ofclarithromycin in the gas-
tricjuice and in the antrum, but not the body ofthe stomach. This contrasts with data sug-
gesting that the concentration ofamoxycillin in the gastric mucosa is higher at a low pH.
Variables in the antisecretory responses to omeprazole may thus contribute to the
observed variations in the omeprazole/amoxycillin data. F. Megraud noted that the MICs
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of amoxycillin and clarithromycin were similar, but that the pharmacokinetics of the
drugs were different. Amoxycillin does not concentrate on the cells, whereas clar-
ithromycin concentrates in the cells and may spread into the overlying mucus during the
next few hours. This was true also for other macrolides such as azithromycin. D. Cave
commented on the different formulations ofamoxycillin, some ofwhich allowed amoxy-
cillin to be released only on the small bowel. F. Megraud stated that IV injections of the
antibiotic gave good results, and that a topical action ofamoxycillin in the stomach was
not necessary.
Consideration was then given to the reason for the low reinfection rate. J. Calam stat-
ed that it was low in the Western World, where there was good hygiene. Data from Brazil
suggested a 21 percent reinfection rate, but there was some doubt as to whether the infec-
tion was cured. He speculated that the organism may be excreted only in children's feces,
but G. Tytgat could not accept this. Persistent immunity was an unlikely explanation
because endoscopic reinfection was very easy - even with meticulous disinfection prac-
tice. F. Megraud agreed that the reinfection rate was very low in the developed world, less
than one percent. Reinfection rates in Brazil were also very low iferadication was checked
by urea breath testing, but ofthe order of25 to 30 percent ifchecked by repeat endoscopy.
R. Huntdid notknow whether PPIs have a specific effect on H. pylori in vivo. He stat-
ed that the growth of the organism is reduced in some patients, that the organisms may
migrate to the fundus, and that its morphology may change. But there was no evidence
regarding specifics such as binding to a P type ATPase or urease inhibition. He did not
regard migration ofthe organism to the fundus, presumably to find a more acid environ-
ment, as a specific PPI effect. The possibility of this being due to a non-specific pH
change was supported by the reportedly good ranitidine/antibiotic data. The allegedly
delayed gastric emptying with H2 blockers or PPIs, allowing a prolonged antibiotic dwell
time in the stomach, should also be considered.
Attention was then focused on the need to test for the presence of H. pyloni before
and aftereradication therapy. The need to test in a patient with duodenal ulcer was unclear
since the chances offinding H. pylori negative is ofthe order ofthree or rour percent; not
much different from the chances offinding a false H. pylori negative result. However, H.
pylori testing should be done at the research or academic level where cost is not a factor.
H. pylori testing after eradication therapy is warranted in complicated ulcer disease, but
probably not in other patients - particularly in those treated with the newer eradication
strategies which assure an eradication rate of over 85 to 90 percent.
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